Web Stats Provided By Google Analytics

Saturday, June 29, 2013

Zyomyx Closes Series 2 Preferred Financing Round of $12 Million to...

... brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers ...

http://www.globenewswire.com/news-release/2013/06/30/557192/10038193/en/Zyomyx-Closes-Series-2-Preferred-Financing-Round-of-12-Million-to-Enable-Launch-of-Low-Cost-Rapid-Point-of-Care-CD4-Test.html

No comments:

Post a Comment